financetom
Business
financetom
/
Business
/
What's Going On With Arista Stock Tuesday?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Arista Stock Tuesday?
Feb 18, 2025 8:14 AM

Arista Networks, Inc. ( ANET ) shares are moving higher on Tuesday. The stock may be moving higher ahead of the company's 2024 fiscal-year fourth-quarter earnings which it’s scheduled to report after the market closes today.

The Details: Analysts estimate earnings per share of 57 cents and revenue of $1.90 billion, according to data from Benzinga Pro. In its third-quarter earnings report, the company guided fourth-quarter revenue to be between $1.85 billion and $1.90 billion.

It also guided a gross margin of about 63% to 64% and an operating margin of approximately 44%.

For the third quarter, the company reported adjusted earnings per share of 60 cents, missing analysts’ estimate of $2.08. In addition, Arista reported revenue of $1.81 billion, beating analysts’ estimate of $1.74 billion.

“Arista remains at the forefront of next-generation centers of data across client-to-cloud and AI-focused locations,” said Jayshree Ullal, Chairperson and CEO of Arista, in the company’s last earnings report.

The company is anticipated to host a live conference call at 4:30 P.M. ET to discuss its financial results.

Related Link: Dell Technologies’s Options: A Look at What the Big Money is Thinking

ANET Price Action: At the time of writing, Arista stock is trading 2.23% higher at $109.26, according to data from Benzinga Pro.

Image: This illustration was generated using artificial intelligence via Midjourney.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Ally Financial's Q2 Adjusted Earnings, Net Revenue Increase
Ally Financial's Q2 Adjusted Earnings, Net Revenue Increase
Jul 18, 2025
07:42 AM EDT, 07/18/2025 (MT Newswires) -- Ally Financial ( ALLY ) reported Q2 adjusted earnings Friday of $0.99 per diluted share, up from $0.73 a year earlier. Analysts polled by FactSet expected $0.81. Net revenue for the quarter ended June 30 was $2.08 billion, compared with $2.02 billion a year earlier. Analysts polled by FactSet expected $2.04 billion. Ally...
Lundin Mining Reports Items Impacting Q2 Results
Lundin Mining Reports Items Impacting Q2 Results
Jul 18, 2025
07:41 AM EDT, 07/18/2025 (MT Newswires) -- Lundin Mining ( LUNMF ) reported overnight Thursday certain items impacting its earnings for the second quarter. The miner expects its revenue to be negatively impacted by provisional pricing adjustments on prior period concentrate sales of about US$6 million on a pre-tax basis. These adjustments primarily include downward adjustments in relation to prior...
Bristol Myers Squibb's Reblozyl Trial for Anemia Fails to Meet Primary Endpoint
Bristol Myers Squibb's Reblozyl Trial for Anemia Fails to Meet Primary Endpoint
Jul 18, 2025
07:41 AM EDT, 07/18/2025 (MT Newswires) -- Bristol Myers Squibb ( BMY ) said Friday that its phase 3 independence trial of Reblozyl in myelofibrosis-associated anemia failed to meet its primary endpoint of transfusion independence. Several secondary endpoints showed meaningful benefits, including reduced transfusion burden and increased hemoglobin levels, the company said. Adverse events were consistent with Reblozyl's known safety...
Copyright 2023-2026 - www.financetom.com All Rights Reserved